Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRE: Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures
2023-506823-28-00Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigimadlin and ezabenlimab in soft tissue sarcoma (STS), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 2 more (2 cohorts), sponsored by Institut Bergonié. Primary endpoint: Disease control rate at 24 weeks (central RECIST v1.1). Started May 2024; status: completed.
02
Drugs
brigimadlinezabenlimab
03
Conditions
soft tissue sarcoma (STS)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)biliary cancer
Beyond the preview
Go deeper on 2023-506823-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506823-28-00.